Ocular Therapeutix 3Q 2026: Revenue $12.87M, EPS ($0.42) — 10-Q Summary

Ocular Therapeutix reported 3Q 2026 revenue of $12.87M, down 11.5% YoY, with a net loss of $94.78M, up 36.5% YoY. The company cited increased R&D costs and higher expenses. DEXTENZA sales declined slightly, while SOL-1 trial met endpoints, with NDA submission expected in Q4 2026.

Original reporting
Published Nov 9, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ocular Therapeutix 3Q 2026: Revenue $12.87M, EPS ($0.42) — 10-Q Summary — source image
Decision brief

The 30-second read

$OCULBearishMed
01

Why it matters

Earnings miss and higher R&D spend suggest short‑term downside, but upcoming NDA filing may offer a catalyst.

02

Market read

First‑time earnings disclosure for a micro‑cap biotech; likely to move the stock in after‑hours trading.

03

What to watch

Potential future NDA filing for SOL-1 could unlock value despite current loss.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

The article summarizes Ocular Therapeutix's Q3 2026 10‑Q filing, highlighting financial declines and ongoing clinical trial modifications.

Company-level read

Ticker impact

$OCULBearishHigh confidence
Context

Q3 2026 results show revenue down 11.5% to $12.87M and net loss widening to $94.78M, with trial updates for SOL-1, SOL-R, and HELIOS-3.

Expected impact

downward pressure as investors price in widening loss and increased R&D spend

Evidence & confidence

Revenue decline and a 36.5% increase in net loss signal weaker near‑term performance; trial setbacks add uncertainty.

Market effects

Biotech sector may see modest pullback as small‑cap trial updates raise risk perception.

U.S. biotech investors could adjust exposure to early‑stage ophthalmic therapies.

Limited; impact confined to niche ophthalmic biotech niche.

Counterpoint

If trial data later prove successful, the stock could rebound sharply on upside potential.

Key entities

  • Ocular Therapeutix

    US‑listed ophthalmic biotech (ticker OCUL).

Related articles

$RKLBMed

Selling Some Rocket Lab After Launch Record

Rocket Lab (RKLB) achieved its 100th Electron launch, deploying a satellite for iQPS. Goldman Sachs raised its target price to $68. ULA's Vulcan rocket failed, destroying Amazon's (AMZN) satellites, halting launches. Analysts adjusted targets for Ondas Inc (ONDS). Peloton (PTON) launched a cheaper treadmill, the Tread Flex, aiming to boost affordability.

$OCULMedAI 8/10

Ocular Therapeutix Inc (OCUL) Q3 2026 Earnings Call Highlights: Landmark Phase 3 Wins, NDA

Ocular Therapeutix (OCUL) reported Q3 2026 earnings, highlighting FDA alignment on SOL-R primary endpoint change to week 40. CEO Pravin Dugel expects NDA submission for AXPAXLI in wet AMD in Q4 2026, with 505(b)(2) pathway potentially shortening review. The company has $530.6M in cash, providing runway into 2028. SOL-1 post-hoc analyses showed strong retinal fluid control and durability. AXPAXLI is positioned as a long-term maintenance therapy in wet AMD, with no direct late-stage competitor.

MedAI 8/10

Ocular Therapeutix, Inc. Q3 2026 Earnings Call Summary

Ocular Therapeutix reported Q3 2026 earnings, highlighting AXPAXLI's clinical success in wet AMD. The company attributes this to axitinib's potency and a maintenance therapy approach. Key data includes 75% of patients maintaining vision at week 36 and 71% being 'quantitatively dry' at week 8. The NDA submission is on track for Q4 2026, with a cash runway into 2028. Management is shifting focus to commercialization and adjusting trial endpoints to protect data integrity.

$OCULMed

Ocular Tx (OCUL) Q3 2026 Earnings Call Transcript

Ocular Tx (OCUL) discussed Q3 2026 earnings, highlighting AXPAXLI's Phase III data in wet AMD. The company emphasized its drug's potency, delivery system, and clinical trial design. OCUL plans to submit an NDA in Q4 2026, aiming for a 505(b)(2) regulatory pathway. SOL-R trial updates showed promising results, with 70% of subjects dry at week 36.

$OCULMed

What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call

Ocular Therapeutix (OCUL) discussed Q3 earnings, noting FDA alignment on endpoint changes for SOL-R and SOL-X studies. Positive data may support commercial use. AXPAXLI showed durability in post-hoc analyses. The company has $530.6M in cash, expected to last into 2028. OCUL is preparing commercial plans for AXPAXLI and continues Phase 3 trials for diabetic retinal disease.